{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:14:29Z","timestamp":1787501669242,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["F32HL165828"],"award-info":[{"award-number":["F32HL165828"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite evidence associating inflammatory biomarkers with worse outcomes in hospitalized adults with COVID-19, trials of immunomodulatory therapies have met with mixed results, likely due in part to biological heterogeneity of participants. Latent class analysis (LCA) of clinical and protein biomarker data has identified two subtypes of non-COVID acute respiratory distress syndrome (ARDS) with different clinical outcomes and treatment responses. We studied biological heterogeneity and clinical outcomes in a multi-institutional platform randomized controlled trial of adults with severe COVID-19 hypoxemic respiratory failure (I-SPY COVID).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinical and plasma protein biomarker data were analyzed from 400 trial participants enrolled from September 2020 until October 2021 with severe COVID-19 requiring\u2009\u2265\u20096 L\/min supplemental oxygen. Seventeen hypothesis-directed protein biomarkers were measured at enrollment using multiplex Luminex panels or single analyte enzyme linked immunoassay methods (ELISA). Biomarkers and clinical variables were used to test for latent subtypes and longitudinal biomarker changes by subtype were explored. A validated parsimonious model using interleukin-8, bicarbonate, and protein C was used for comparison with non-COVID hyper- and hypo-inflammatory ARDS subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Average participant age was 60\u2009\u00b1\u200914\u00a0years; 67% were male, and 28-day mortality was 25%. At trial enrollment, 85% of participants required high flow oxygen or non-invasive ventilation, and 97% were receiving dexamethasone. Several biomarkers of inflammation (IL-6, IL-8, IL-10, sTNFR-1, TREM-1), epithelial injury (sRAGE), and endothelial injury (Ang-1, thrombomodulin) were associated with 28- and 60-day mortality. Two latent subtypes were identified. Subtype 2 (27% of participants) was characterized by persistent derangements in biomarkers of inflammation, endothelial and epithelial injury, and disordered coagulation and had twice the mortality rate compared with Subtype 1. Only one person was classified as hyper-inflammatory using the previously validated non-COVID ARDS model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We discovered evidence of two novel biological subtypes of severe COVID-19 with significantly different clinical outcomes. These subtypes differed from previously established hyper- and hypo-inflammatory non-COVID subtypes of ARDS. Biological heterogeneity may explain inconsistent findings from trials of hospitalized patients with COVID-19 and guide treatment approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13054-024-04819-0","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T08:02:14Z","timestamp":1708502534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial"],"prefix":"10.1186","volume":"28","author":[{"given":"Narges","family":"Alipanah-Lechner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hurst-Hopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Delucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamorna","family":"Swigart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Willmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"LaCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Dewar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Clifford","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Lallemand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen D.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Matthay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.","family":"Calfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the I-SPY COVID Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil R.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Albertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Auld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy R.","family":"Beitler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen L.","family":"Burnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Crippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Discacciati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Clark","family":"Files","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheetal","family":"Gandotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Koff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuala J.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Obermiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Fum","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Wunderink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M.","family":"Wurfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady A.","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Darmanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Dzierba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Gosek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purnema","family":"Madahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M.","family":"Mittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis L.","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigha","family":"Landreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"LaRose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A. G.","family":"Ittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilam S.","family":"Mangalmurti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Methukupally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsie","family":"Boerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kazianis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"McKeehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Fields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Jauregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Belvins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged A.","family":"Tanios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farjad","family":"Sarafian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Adelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Creel-Bulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Detelich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Spainhour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Haczku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richart","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Morrissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sandrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. R. Scott","family":"Budinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen K.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Levitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Asare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imogene","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro Botello","family":"Barragan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"issue":"5","key":"4819_CR1","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.cell.2020.08.021","volume":"182","author":"DM Morens","year":"2020","unstructured":"Morens DM, Fauci AS. Emerging Pandemic Diseases: How We Got to COVID-19. Cell. 2020;182(5):1077\u201392. https:\/\/doi.org\/10.1016\/j.cell.2020.08.021.","journal-title":"Cell"},{"key":"4819_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1985","volume":"369","author":"AB Docherty","year":"2020","unstructured":"Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369: m1985. https:\/\/doi.org\/10.1136\/bmj.m1985.","journal-title":"BMJ"},{"key":"4819_CR3","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.15.20067157","author":"MJ Cummings","year":"2020","unstructured":"Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.15.20067157.","journal-title":"medRxiv"},{"issue":"7","key":"4819_CR4","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","volume":"184","author":"JL Schultze","year":"2021","unstructured":"Schultze JL, Aschenbrenner AC. COVID-19 and the human innate immune system. Cell. 2021;184(7):1671\u201392. https:\/\/doi.org\/10.1016\/j.cell.2021.02.029.","journal-title":"Cell"},{"issue":"8","key":"4819_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384(8):693\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2021436.","journal-title":"N Engl J Med"},{"key":"4819_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17021","author":"B Tomazini","year":"2020","unstructured":"Tomazini B, Maia I, Cavalcanti A, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.17021.","journal-title":"JAMA"},{"key":"4819_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16761","author":"P Dequin","year":"2020","unstructured":"Dequin P, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.16761.","journal-title":"JAMA"},{"key":"4819_CR8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02532-2021","author":"K Crothers","year":"2022","unstructured":"Crothers K, DeFaccio R, Tate J, et al. Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.02532-2021.","journal-title":"Eur Respir J"},{"issue":"13","key":"4819_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2020.17022","volume":"324","author":"DC Angus","year":"2020","unstructured":"Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317\u201329. https:\/\/doi.org\/10.1001\/jama.2020.17022.","journal-title":"JAMA"},{"key":"4819_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6615","author":"C Salvarani","year":"2021","unstructured":"Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021. https:\/\/doi.org\/10.1001\/jamainternmed.2020.6615.","journal-title":"JAMA Intern Med"},{"key":"4819_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.6820","author":"O Hermine","year":"2021","unstructured":"Hermine O, Mariette X, Tharaux P, Resche-Rigon M, Porcher R, Ravaud P. Effect of tocilizumab vs usual care in adults hospitalized With COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021. https:\/\/doi.org\/10.1001\/jamainternmed.2020.6820.","journal-title":"JAMA Intern Med"},{"issue":"16","key":"4819_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"A Gordon","year":"2021","unstructured":"Gordon A, Mouncey P, Al-Beidh F, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):25. https:\/\/doi.org\/10.1056\/NEJMoa2100433.","journal-title":"N Engl J Med"},{"key":"4819_CR13","doi-asserted-by":"publisher","unstructured":"Rosas IO, Br\u00e4u N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. https:\/\/doi.org\/10.1056\/NEJMoa2028700 2021 (research-article) (in English).","DOI":"10.1056\/NEJMoa2028700"},{"key":"4819_CR14","doi-asserted-by":"publisher","unstructured":"Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. 2021 (in English). https:\/\/doi.org\/10.1136\/bmj.n84.","DOI":"10.1136\/bmj.n84"},{"issue":"5","key":"4819_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2213-2600(21)00081-3","volume":"9","author":"AS Soin","year":"2021","unstructured":"Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021;9(5):511\u201321. https:\/\/doi.org\/10.1016\/S2213-2600(21)00081-3.","journal-title":"Lancet Respir Med"},{"key":"4819_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00485-0","author":"F Ader","year":"2021","unstructured":"Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021. https:\/\/doi.org\/10.1016\/S1473-3099(21)00485-0.","journal-title":"Lancet Infect Dis"},{"key":"4819_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England). 2020;395:25. https:\/\/doi.org\/10.1016\/S0140-6736(20)31022-9.","journal-title":"Lancet (London, England)"},{"issue":"19","key":"4819_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"J Beigel","year":"2020","unstructured":"Beigel J, Tomashek K, Dodd L, et al. Remdesivir for the treatment of Covid-19\u2014final report. N Engl J Med. 2020;383(19):25. https:\/\/doi.org\/10.1056\/NEJMoa2007764.","journal-title":"N Engl J Med"},{"key":"4819_CR19","doi-asserted-by":"publisher","unstructured":"Consortium WST. Repurposed antiviral drugs for Covid-19\u2014interim WHO solidarity trial results. https:\/\/doi.org\/10.1056\/NEJMoa2023184 2020 (research-article) (in English).","DOI":"10.1056\/NEJMoa2023184"},{"issue":"8","key":"4819_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S2213-2600(14)70097-9","volume":"2","author":"C Calfee","year":"2014","unstructured":"Calfee C, Delucchi K, Parsons P, Thompson B, Ware L, Matthay M. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):25. https:\/\/doi.org\/10.1016\/S2213-2600(14)70097-9.","journal-title":"Lancet Respir Med"},{"key":"4819_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30177-2","author":"C Calfee","year":"2018","unstructured":"Calfee C, Delucchi K, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018. https:\/\/doi.org\/10.1016\/S2213-2600(18)30177-2.","journal-title":"Lancet Respir Med"},{"key":"4819_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5378-3","author":"P Sinha","year":"2018","unstructured":"Sinha P, Delucchi K, Thompson B, McAuley D, Matthay M, Calfee C. Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med. 2018. https:\/\/doi.org\/10.1007\/s00134-018-5378-3.","journal-title":"Intensive Care Med"},{"key":"4819_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217158","author":"P Sinha","year":"2021","unstructured":"Sinha P, Delucchi KL, Chen Y, et al. Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: a prospective study. Thorax. 2021. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-217158. (in English).","journal-title":"Thorax"},{"key":"4819_CR24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201603-0645OC","author":"K Famous","year":"2017","unstructured":"Famous K, Delucchi K, Ware L, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017. https:\/\/doi.org\/10.1164\/rccm.201603-0645OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"4819_CR25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202105-1302OC","author":"P Sinha","year":"2021","unstructured":"Sinha P, Furfaro D, Cummings MJ, et al. Latent class analysis reveals COVID-19-related ARDS subgroups with differential responses to corticosteroids. Am J Respir Crit Care Med. 2021. https:\/\/doi.org\/10.1164\/rccm.202105-1302OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"4819_CR26","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/S2213-2600(20)30366-0","volume":"8","author":"P Sinha","year":"2020","unstructured":"Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. Lancet Respir Med. 2020;8(12):1209\u201318. https:\/\/doi.org\/10.1016\/S2213-2600(20)30366-0.","journal-title":"Lancet Respir Med"},{"key":"4819_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100829","volume":"34","author":"S Ranjeva","year":"2021","unstructured":"Ranjeva S, Pinciroli R, Hodell E, et al. Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019. EClinicalMedicine. 2021;34: 100829. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100829.","journal-title":"EClinicalMedicine"},{"issue":"12","key":"4819_CR28","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1097\/CCM.0000000000005983","volume":"51","author":"PA Verhoef","year":"2023","unstructured":"Verhoef PA, Spicer AB, Lopez-Espina C, et al. Analysis of protein biomarkers from hospitalized COVID-19 patients reveals severity-specific signatures and two distinct latent profiles with differential responses to corticosteroids. Crit Care Med. 2023;51(12):1697\u2013705. https:\/\/doi.org\/10.1097\/CCM.0000000000005983.","journal-title":"Crit Care Med"},{"issue":"6","key":"4819_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060664","volume":"12","author":"DC Files","year":"2022","unstructured":"Files DC, Matthay MA, Calfee CS, et al. I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations. BMJ Open. 2022;12(6): e060664. https:\/\/doi.org\/10.1136\/bmjopen-2021-060664.","journal-title":"BMJ Open"},{"key":"4819_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101889","volume":"58","author":"Consortium ISC","year":"2023","unstructured":"Consortium ISC. Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial. EClinicalMedicine. 2023;58: 101889. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101889.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"4819_CR31","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1097\/CCM.0000000000004710","volume":"49","author":"P Sinha","year":"2021","unstructured":"Sinha P, Calfee CS, Delucchi KL. Practitioner\u2019s guide to latent class analysis: Methodological considerations and common pitfalls. Crit Care Med. 2021;49(1):e63\u201379. https:\/\/doi.org\/10.1097\/CCM.0000000000004710.","journal-title":"Crit Care Med"},{"issue":"3","key":"4819_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S2213-2600(19)30369-8","volume":"8","author":"P Sinha","year":"2020","unstructured":"Sinha P, Delucchi KL, McAuley DF, O\u2019Kane CM, Matthay MA, Calfee CS. Development and validation of parsimonious algorithms to classify acute respiratory distress syndrome phenotypes: a secondary analysis of randomised controlled trials. Lancet Respir Med. 2020;8(3):247\u201357. https:\/\/doi.org\/10.1016\/S2213-2600(19)30369-8.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"4819_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/biomet\/88.3.767","volume":"88","author":"Y Lo","year":"2001","unstructured":"Lo Y, Mendell NR, Rubin DB. Testing the number of components in a normal mixture. Biometrika. 2001;88(3):767\u201378.","journal-title":"Biometrika"},{"issue":"2","key":"4819_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/10705510709336744","volume":"14","author":"JM Henson","year":"2007","unstructured":"Henson JM, Reise SP, Kim KH. Detecting mixtures from structural model differences using latent variable mixture modeling: a comparison of relative model fit statistics. Struct Eq Model Multidiscip J. 2007;14(2):202\u201326.","journal-title":"Struct Eq Model Multidiscip J"},{"key":"4819_CR35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","author":"P Horby","year":"2021","unstructured":"Horby P, Lim W, Emberson J, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2021436.","journal-title":"N Engl J Med"},{"issue":"10285","key":"4819_CR36","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"Group RC","year":"2021","unstructured":"Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10285):1637\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(21)00676-0.","journal-title":"Lancet"},{"issue":"16","key":"4819_CR37","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","volume":"384","author":"IO Rosas","year":"2021","unstructured":"Rosas IO, Brau N, Waters M, et al. Tocilizumab in hospitalized patients with severe covid-19 pneumonia. N Engl J Med. 2021;384(16):1503\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2028700.","journal-title":"N Engl J Med"},{"issue":"1","key":"4819_CR38","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2030340","volume":"384","author":"C Salama","year":"2021","unstructured":"Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2030340.","journal-title":"N Engl J Med"},{"key":"4819_CR39","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202303-0558WS","author":"MA Matthay","year":"2023","unstructured":"Matthay MA, Arabi Y, Arroliga AC, et al. A new global definition of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2023. https:\/\/doi.org\/10.1164\/rccm.202303-0558WS.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"4819_CR40","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41591-022-01843-x","volume":"28","author":"DM Maslove","year":"2022","unstructured":"Maslove DM, Tang B, Shankar-Hari M, et al. Redefining critical illness. Nat Med. 2022;28(6):1141\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01843-x.","journal-title":"Nat Med"},{"issue":"8","key":"4819_CR41","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/cid\/ciaa449","volume":"71","author":"X Chen","year":"2020","unstructured":"Chen X, Zhao B, Qu Y, et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) Is closely correlated with drastically elevated interleukin 6 level in critically Ill patients with coronavirus disease 2019. Clin Infect Dis. 2020;71(8):1937\u201342. https:\/\/doi.org\/10.1093\/cid\/ciaa449.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4819_CR42","doi-asserted-by":"publisher","first-page":"e799","DOI":"10.1093\/cid\/ciaa1338","volume":"73","author":"C Prebensen","year":"2021","unstructured":"Prebensen C, Myhre PL, Jonassen C, et al. Severe acute respiratory syndrome coronavirus 2 RNA in plasma is associated with intensive care unit admission and mortality in patients hospitalized with coronavirus disease 2019. Clin Infect Dis. 2021;73(3):e799\u2013802. https:\/\/doi.org\/10.1093\/cid\/ciaa1338.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4819_CR43","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s13054-020-03398-0","volume":"24","author":"JF Bermejo-Martin","year":"2020","unstructured":"Bermejo-Martin JF, Gonzalez-Rivera M, Almansa R, et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Crit Care. 2020;24(1):691. https:\/\/doi.org\/10.1186\/s13054-020-03398-0.","journal-title":"Crit Care"},{"issue":"1","key":"4819_CR44","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13054-022-04153-3","volume":"26","author":"KD Wick","year":"2022","unstructured":"Wick KD, Leligdowicz A, Willmore A, et al. Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19. Crit Care. 2022;26(1):278. https:\/\/doi.org\/10.1186\/s13054-022-04153-3.","journal-title":"Crit Care"},{"issue":"10","key":"4819_CR45","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.7326\/M22-0924","volume":"175","author":"AJ Rogers","year":"2022","unstructured":"Group A-TS, Rogers AJ, Wentworth D, et al. The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. Ann Intern Med. 2022;175(10):1401\u201310. https:\/\/doi.org\/10.7326\/M22-0924.","journal-title":"Ann Intern Med"},{"issue":"1","key":"4819_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jaci.2020.10.001","volume":"147","author":"M Van Singer","year":"2021","unstructured":"Van Singer M, Brahier T, Ngai M, et al. COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department. J Allergy Clin Immunol. 2021;147(1):99-106 e4. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.001.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"4819_CR47","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1042\/BSR20210940","volume":"41","author":"AH de Nooijer","year":"2021","unstructured":"de Nooijer AH, Grondman I, Lambden S, et al. Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19. Biosci Rep. 2021;41(7):25.","journal-title":"Biosci Rep"},{"key":"4819_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102013","volume":"60","author":"B Francois","year":"2023","unstructured":"Francois B, Lambden S, Garaud JJ, et al. Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial. EClinicalMedicine. 2023;60: 102013. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102013.","journal-title":"EClinicalMedicine"},{"issue":"9","key":"4819_CR49","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2213-2600(21)00237-X","volume":"9","author":"J Aman","year":"2021","unstructured":"Aman J, Duijvelaar E, Botros L, et al. Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respir Med. 2021;9(9):957\u201368. https:\/\/doi.org\/10.1016\/S2213-2600(21)00237-X.","journal-title":"Lancet Respir Med"},{"key":"4819_CR50","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00780-2022","author":"J de Brabander","year":"2022","unstructured":"de Brabander J, Duijvelaar E, Schippers JR, et al. Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients. Eur Respir J. 2022. https:\/\/doi.org\/10.1183\/13993003.00780-2022.","journal-title":"Eur Respir J"},{"key":"4819_CR51","unstructured":"McAuley D. Clinical evaluation of a point of care (POC) assay to identify phenotypes in the acute respiratory distress syndrome\u2014Full Text View\u2014Clinical.Trials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04009330."}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-04819-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-024-04819-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-04819-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T08:07:38Z","timestamp":1708502858000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-024-04819-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4819"],"URL":"https:\/\/doi.org\/10.1186\/s13054-024-04819-0","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The I-SPY COVID trial is conducted under a central IRB mechanism (Wake Forest University Health Sciences IRB00066805). The trial was conducted in accordance with Good Clinical Practice guidelines and the Helsinki Declaration, and all participants, or their surrogates, provided informed consent prior to enrollment in the interventional arm of the study. The University of California, San Francisco internal review board approved the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}